Syntara Limited is a clinical-stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.
Price delay between 20-60 minutes.
First interventional study to directly target neuroinflammation in patients with isolated REM Sleep Behaviour Disorder (iRBD) and interrogate the disease biology underlying…
Innovative Phase 1b trial of SNT-9465 in hypertrophic scars exceeds 50% recruitment Pilot cohort data confirm high baseline lysyl oxidase activity, validating…
Syntara CEO Gary Phillips hosted an investor webinar to discuss recent updates, including the positive FDA feedback supporting the planned Phase 2b…
Syntara has received firm commitments from existing and new institutional and sophisticated investors to raise A$8.0 million (before costs) by way of…
Positive Type C meeting outcome with US FDA supporting the Phase 2b design for Syntara’s lead asset amsulostat Amsulostat on target to…
Syntara has received a milestone payment of approximately A$1.7 million (£900,000) from Parkinson’s UK, triggered by dosing of the final patient in its…
Positive final Phase 2a amsulostat data webinar presentation
Investor presentation – Euroz Hartleys 2024 Healthcare Forum
December 2023 – investor presentation for shareholder briefing
September 2023 – investor presentation for shareholder briefing
December 2022 – investor presentation for shareholder briefing
ASX Briefs: How Syntara Builds A Biotech Pipeline With Multiple Shots On Goal
ShareCafe: Syntara Receives Positive FDA Feedback for Myelofibrosis Drug Amsulostat
Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that
Syntara Topical Pan-Lox Inhibition for Skin Scarring KOL webinar with Prof. Ardeshir Bayat
Syntara Investor Webinar Replay — Amsulostat Clinical Pathway
Syntara (ASX: SNT) Presentation | NWR Virtual Healthcare Conference
Stockhead: Dr Boreham’s Crucible (also included in Biotech Daily)
Syntara (ASX:SNT) Skin Scarring webinar featuring world-renowned skin scarring expert Fiona Wood
Stockhead: Syntara’s burns treatment cleans up unsightly scars
Phase 2 SNT-5505 interim myelofibrosis data read out webinar
Syntara CEO Talks JustStocks Video Through Positive Interim Data In Lead Myelofibrosis Trial
9News: World-first trial to understand link between violent dreams and Parkinson’s disease
Syntara CEO Gary Phillips Updates JustStocks Video On Blood Cancer Trial And Upcoming Catalysts
Syntara CEO Gary Phillips Speaks With JustStocks Video As Phase 2 Blood Cancer Trial Fully Recruits
Proactive interview: Syntara to start Phase 2 study targeting MDS
Proactive interview: Syntara raising $10 million to support for three phase 2 clinical trials
Proactive interview: Syntara doses first patient in phase 2 blood cancer study
Pharmaxis (ASX: PXS) Investor Briefing – Company Restructure
Investor briefing – phase 2 cancer clinical trial interim results
Investor briefing – phase 1c established scar clinical trial top line results
Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks
Euroz Hartleys: Positive FDA Feedback Received; Several Major Catalysts Ahead
Euroz Hartleys: Interview with Former CEO Behind a US$1.7Bn Myelofibrosis Exit
Euroz Hartleys: Haematology Continues to Attract Pharma Interest
Euroz Hartleys: SNT: Final Phase 2 Results; Global Experts to Support Next Stage of Development
Kicking off FY25 with Important Trial Fully Recruited, $5.0m Capital Raise
MST Access: More shots on goal – new blood cancer indication for SNT-5505
MST Access: 1Q: Refocused Business Cutting Expenses, Progressing Trials
Bioshares: Pharmaxis – meaningful impact on bone marrow in myelofibrosis study
Taylor Collison: Progressing to next stage in scarring and myelofibrosis
Bioshares: Mixed results from Pharmaxis’ scar treatment study
MST Access: Pleasing results from established scars, phase 1c – more to come
MST Access: 3Q: cash balance comfortable as key trials proceed in tandem
MST Access: Useful FDA feedback paves way for new arm of lead clinical trial
MST Access: Raising PXS-5505 profile in new indication, synergies with SOC
MST Access: 2QFY23 – news flow plentiful in 2023 with data readouts from two major trials
Syntara Limited (ABN 75 082 811 630) is listed on the Australian Securities Exchange, code SNT. Syntara Limited was named Pharmaxis Ltd until 4 December 2023. It’s ASX code was PXS. The Syntara website is current for all investor information from 4 December 2023, with select historical information provided for ease of use. For a complete archive of historical information visit the ASX website.